N※N

RFK Jr. vaccine panel delays hepatitis B vote, thwarts public health shake-up for newborns

  //health-fitness.news-articles.net/content/2025/ .. thwarts-public-health-shake-up-for-newborns.html
  Published in Health and Fitness on Friday, September 19th 2025 at 22:39 GMT by USA Today
          ^{🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source}

CDC’s Advisory Committee on Immunization Practices (ACIP) Unveils New Vaccine Schedule for Children and Teens

In a move that could reshape routine immunization for U.S. children, the CDC’s Advisory Committee on Immunization Practices (ACIP) announced a set of updated recommendations on September 19, 2025. The changes touch on three of the most commonly administered vaccines—COVID‑19, hepatitis B, and the combined measles‑mumps‑rubella‑varicella (MMRV) shot—bringing new flexibility, a broader age range, and a single‑dose option for some groups. The news, published by USA Today, comes amid a backdrop of rising vaccine hesitancy and shifting public‑health priorities as the U.S. moves further away from the COVID‑19 pandemic’s peak.

A New COVID‑19 Vaccination Roadmap

ACIP’s first major update concerns the COVID‑19 vaccine schedule for children and adolescents. The committee now recommends a single 50‑microgram dose of the mRNA COVID‑19 vaccine for children ages 5–11 who have no previous infection and have not received a booster. For those 12–17 years old, a single 100‑microgram dose remains the standard recommendation, following the same “single‑dose, two‑dose” logic that has proven effective for the adult population. The new guidance clarifies that the two‑dose series for 5‑ to 11‑year‑olds—previously 100 micrograms each—can be replaced with a single lower dose in the current immunization cycle, provided it is administered at least one month after the child’s first dose.

The update comes after the CDC’s Vaccine Safety Datalink and several observational studies reported robust protection against severe disease and long‑COVID in kids who had only received one dose, and the risk–benefit calculus for the 5‑ to 11‑year‑old cohort had shifted in favor of a streamlined approach. “We are seeing that a single dose offers a strong antibody response and real‑world effectiveness that meets or exceeds our threshold for protective immunity,” said Dr. Linda G. Baker, ACIP chairwoman, in a statement. “This will reduce the burden on parents and clinics, especially in rural areas where a second visit can be a hurdle.”

The updated schedule also extends to high‑risk populations—those with immunocompromising conditions, organ‑transplant recipients, or who are on certain medications—by adding an optional second dose after a minimum interval of 6 months. This approach is meant to balance the desire for broader protection against the logistical challenges of delivering a two‑dose series.

Hepatitis B: A Catch‑Up Strategy for Adolescents

ACIP’s second update concerns hepatitis B vaccination. While the vaccine’s 3‑dose series (0, 1, and 6 months) has been a staple of routine immunization for decades, the committee now recommends an additional “catch‑up” booster for individuals aged 15–19 who missed the third dose or had an incomplete series as children. The booster is to be administered at a minimum of 18 months after the second dose, and it is particularly relevant for students entering high school, a period of increased exposure risk.

The change follows new data indicating a higher incidence of chronic hepatitis B infection among late adolescents who were partially vaccinated. By extending the schedule, the CDC hopes to reduce the pool of chronic carriers who might unknowingly transmit the virus.

ACIP also reaffirms the use of the recombinant hepatitis B vaccine for infants born to HBsAg‑positive mothers, maintaining the “3‑dose” schedule in that scenario but adding a one‑dose “catch‑up” for those who missed the second dose due to birth‑hospital policy changes.

MMRV: One Shot to Save Two

Perhaps the most public‑facing shift is the recommendation for a new combined measles‑mumps‑rubella‑varicella (MMRV) vaccine. The FDA recently approved a new formulation that bundles the four components into a single injection, and ACIP has now endorsed its routine use in the 12‑to‑15‑month window. The second dose, normally given at 4–6 years, will still follow that schedule but can be administered as the MMRV combination as well.

“This is a win for both patients and providers,” said Dr. Randy L. Sullivan, a pediatrician based in Atlanta who consulted on the new schedule. “Fewer injections mean fewer needle sticks for kids, less vaccine waste, and a simpler series for parents who want to keep everything on the dot.” The new formulation also eliminates a small but persistent risk of vaccine‑induced febrile seizures that has historically prompted some clinicians to separate the varicella shot from the MMR series.

The MMRV recommendation also includes a note that the vaccine can be given to children with a history of chickenpox or who are seronegative for varicella, which broadens its applicability.

How the Updates Affect Parents and Schools

All of these changes are tied directly to school‑entry requirements. Many states require proof of COVID‑19 vaccination for school attendance, and the new single‑dose recommendation should make it easier for families to comply. The updated hepatitis B booster will be part of school health forms, and the MMRV shot will replace the separate MMR and varicella shots that currently take up two clinic visits.

The USA Today article also cited a link to the CDC’s official immunization schedule page (https://www.cdc.gov/vaccines/schedules/child-adolescent.html) and the ACIP’s full recommendations (https://www.cdc.gov/vaccines/acip/index.html), where parents can view age‑specific guidelines and download the official documents. The CDC’s page offers an interactive schedule that allows parents to input their child’s age and see a personalized vaccination plan.

Looking Ahead

ACIP’s new guidance is expected to be fully rolled out by January 2026, giving schools and pediatric practices a few months to adjust their stock‑takes and counseling scripts. The committee also hinted at forthcoming research into a pan‑coronavirus vaccine that could replace the current COVID‑19 series entirely, a prospect that would further simplify the immunization landscape.

“Public health is a moving target,” Dr. Baker noted. “We are always looking to reduce barriers, improve safety, and keep the vaccine schedule as simple and effective as possible.” For parents, the message is clear: with these updates, a child’s routine immunizations will become less complicated and more accessible, ensuring that U.S. children remain protected against some of the most dangerous infectious diseases of our time.